Skip to main content
. 2016 Aug 23;57(2):161–172. doi: 10.1002/jcph.791

Figure 4.

Figure 4

(A) Lulizumab suppression on KLH‐induced IgG response at days 8, 15, and 29 after single IV dose administration in healthy subjects in the SAD study; (B) mean CD4 cell CD28 receptor occupancy in the KLH panels of the SAD study. IgG, immunoglobulin G; IV, intravenous; KLH, keyhole limpet hemocyanin; SAD, single‐ascending dose.